What question did this study set out to answer?

To evaluate the role of ITGB4 protein expression as a biomarker in predicting treatment sensitivity in breast cancer.

April 24, 2026The Breast Journal0 citationsOpen Access

Integrin Beta 4 Protein Expression Bimodally Predicts Sensitivity to CDK4/6 Inhibition and Resistance to Immunotherapy in Breast Cancer

ZZZhimin ZhuShanghai Eighth People Hospital LHL X HuPeking University YMYan-Wen MaWenzhou Medical University

Key Points

To evaluate the role of ITGB4 protein expression as a biomarker in predicting treatment sensitivity in breast cancer.
Assessment of ITGB4 protein expression levels in breast cancer subtypes.
Evaluation of sensitivity to CDK4/6 inhibitors in luminal subtypes.
Analysis of immunotherapy resistance in triple-negative breast cancer (TNBC).
ITGB4 expression predicts sensitivity to CDK4/6 inhibitors in luminal breast cancer subtypes.
High ITGB4 levels indicate resistance to immunotherapy in TNBC.
ITGB4 serves as a critical biomarker for personalized therapy.

Abstract

ITGB4 protein expression serves as a bimodal biomarker in breast cancer, predicting CDK4/6 inhibitor sensitivity in luminal subtypes while indicating immunotherapy resistance in TNBC. ITGB4 protein thus represents a critical biomarker for guiding personalized therapy in precision oncology.

Ask AI

Helpful

Bookmark

View Full Paper